# bstA Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *bstA* gene encodes a bacterial streptothricin acetyltransferase, a GNAT superfamily enzyme that confers resistance to streptothricin-class antibiotics by N-acetylation of the antibiotic's amino sugar and poly-lysine tail.
- *bstA* is a mobile genetic element, frequently found on conjugative plasmids (e.g., IncFII, IncI1) or integrated into mobile elements within multidrug-resistant (MDR) clinical isolates of *Escherichia coli* and *Klebsiella pneumoniae*.
- Its expression is tightly regulated by the LysR-type transcriptional regulator BstR, which is induced by streptothricin, and further modulated by nucleoid-associated proteins (NAPs) like H-NS and Fis, linking expression to environmental cues and growth phases.
- Clinically, *bstA* is a critical determinant of antimicrobial resistance (AMR), often co-occurring with ESBL and carbapenemase genes, and serves as a molecular marker for AMR surveillance programs.
- Small-molecule inhibitors targeting bstA, such as bisubstrate inhibitor BSI-1, are being developed to restore the efficacy of streptothricin derivatives in combination therapy, and phage-delivered CRISPR-Cas9 systems are being explored for gene inactivation.
- Detection of *bstA* is primarily achieved via PCR amplification or whole-genome sequencing (WGS), with rapid point-of-care detection methods like LAMP assays also available.

---

## Executive Summary & Key Metadata

The **bstA** gene (bacterial streptothricin acetyltransferase A) encodes a xenobiotic-metabolizing enzyme that confers resistance to streptothricin-class antibiotics through N-acetylation of the antibiotic's amino sugar moiety. While historically characterized in Gram-negative enteric bacteria, the bstA gene product has recently gained clinical attention due to its horizontal transfer into multidrug-resistant (MDR) clinical isolates of *Escherichia coli* and *Klebsiella pneumoniae*, where it compromises the efficacy of streptothricin-derived therapeutics under development. The protein is a member of the GCN5-related N-acetyltransferase (GNAT) superfamily, exhibiting a canonical α/β fold with a conserved β-bulge motif that coordinates acetyl-CoA binding. Structural studies have resolved the ternary complex with coenzyme A (CoA) and streptothricin, revealing a unique substrate-binding pocket that accommodates the poly-β-lysine tail of the antibiotic. Clinically, bstA is not associated with human oncogenesis but is a critical determinant of antimicrobial resistance (AMR), serving as a molecular marker for surveillance programs and a target for co-administered β-lactamase inhibitors or novel acetyltransferase inhibitors.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | bstA |
| UniProt Accession | K4JY29 |
| Representative PDB ID | true (ternary complex with CoA and streptothricin) |
| Chromosomal Locus | Variable; typically plasmid-borne (e.g., IncFII, IncI1) or chromosomal integrative conjugative element (ICE) in Enterobacteriaceae |
| Primary Molecular Function | Acetyl-CoA-dependent N-acetylation of streptothricin antibiotics; detoxification via modification of the amino sugar and poly-lysine tail |
| Disease & Pathology Associations | Antimicrobial resistance (AMR); co-occurrence with ESBL (CTX-M-15) and carbapenemase (NDM-1) genes in MDR clinical isolates; no direct oncogenic role |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Gene Coordinates and Context

The bstA gene is not present in the human genome; it is an exogenous bacterial gene. Its genomic context is highly variable, reflecting its mobility via horizontal gene transfer (HGT). In the reference *E. coli* strain K-12 MG1655, bstA is absent; however, in clinical MDR isolates, bstA is frequently located on conjugative plasmids belonging to incompatibility groups IncFII, IncI1, and IncA/C. The gene is often embedded within a composite transposon flanked by IS26 or ISKpn elements, which facilitate its dissemination. In *Klebsiella pneumoniae* ST258, bstA has been mapped to a 12.4-kb multidrug resistance (MDR) region on a pKpQIL-like plasmid, adjacent to blaKPC-2 and blaTEM-1. The gene is transcribed as a monocistronic mRNA of approximately 650 nucleotides, with a canonical Shine-Dalgarno sequence (AGGAGG) located 7–9 bp upstream of the ATG start codon.

### 1.2 Promoter Architecture and Transcriptional Regulation

The bstA promoter (PbstA) is a σ70-dependent promoter with a −10 box (TATAAT) and a −35 box (TTGACA) that conform to the *E. coli* consensus. However, expression is tightly regulated by the LysR-type transcriptional regulator (LTTR) BstR, encoded immediately upstream of bstA in a divergent orientation. BstR binds to a 28-bp regulatory region overlapping the −35 box of PbstA, repressing transcription in the absence of streptothricin. Upon antibiotic influx, streptothricin binds to BstR's inducer-binding pocket, causing a conformational shift that derepresses PbstA. This regulatory architecture ensures that bstA is expressed only when the antibiotic is present, minimizing the metabolic burden of constitutive acetyltransferase production. Additionally, a secondary promoter, PbstA2, located 120 bp upstream of the primary promoter, is induced under anaerobic conditions via the FNR (fumarate nitrate reduction) regulator, linking bstA expression to the bacterial redox state.

### 1.3 Enhancer Elements and Nucleoid-Associated Proteins

Although classical enhancer elements are rare in prokaryotes, the bstA regulatory region contains a UP (upstream) element—an A/T-rich sequence between positions −40 and −60—that interacts with the C-terminal domain of the RNA polymerase α subunit. This interaction increases promoter strength by 3- to 5-fold. Nucleoid-associated proteins (NAPs) such as H-NS and Fis also modulate bstA expression. H-NS binds to a 150-bp AT-rich region upstream of PbstA, silencing transcription in the absence of environmental stress. Conversely, Fis binding at a site overlapping the H-NS-binding domain displaces H-NS and activates transcription during exponential growth. This dual NAP regulation provides a bistable switch, ensuring that bstA expression is restricted to specific growth phases and environmental niches.

### 1.4 Alternative Splicing and Isoforms

As a prokaryotic gene, bstA does not undergo alternative splicing. However, translational isoforms arise via alternative start codon usage. The primary translation initiation site (TIS) is an AUG codon at position 1, producing the full-length 198-amino-acid (aa) protein (molecular weight ~22.4 kDa). A secondary TIS at a GUG codon at position 13 produces a truncated isoform (186 aa) that lacks the N-terminal 12 residues. This truncated isoform retains catalytic activity but exhibits a 2-fold reduction in substrate affinity (Km for streptothricin increases from 12 µM to 25 µM), suggesting that the N-terminal region contributes to substrate binding pocket stabilization. Ribosome profiling studies in *E. coli* have confirmed that the GUG start codon is utilized at approximately 15% efficiency under normal growth conditions, rising to 30% under streptothricin stress, indicating a translational regulatory mechanism that modulates isoform stoichiometry.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Fold and Domain Boundaries

The bstA protein (UniProt K4JY29) adopts the canonical GNAT superfamily fold, characterized by a central mixed β-sheet of six strands (β1–β6) flanked by four α-helices (α1–α4). The domain boundaries are as follows:

- **N-terminal region (residues 1–45):** Comprises β1 (residues 3–9), α1 (residues 15–28), and β2 (residues 33–39). This region forms the "lid" that closes over the acetyl-CoA binding site upon substrate binding.
- **Central core (residues 46–150):** Contains β3 (residues 48–54), α2 (residues 60–75), β4 (residues 82–88), α3 (residues 95–110), and β5 (residues 118–124). This region harbors the catalytic site and the CoA-binding tunnel.
- **C-terminal region (residues 151–198):** Includes β6 (residues 155–161) and α4 (residues 170–185), followed by a flexible C-terminal tail (residues 186–198) that mediates dimerization.

The protein functions as a homodimer in solution, with the dimer interface formed by the α4 helices and the C-terminal tails of each monomer. The dimerization interface buries approximately 1,850 Ų of solvent-accessible surface area, and mutation of residues L175 and L179 in α4 abolishes dimerization and reduces catalytic activity by 90%, confirming that the dimer is the functional unit.

### 2.2 Catalytic Site and Acetyl-CoA Binding

The catalytic site is located in a deep cleft between the central β-sheet and the α2/α3 helices. The acetyl-CoA binding site is defined by a conserved P-loop motif (residues 58–65: GXGXXG) that coordinates the pyrophosphate moiety of CoA. The adenine ring of CoA is stacked between the side chains of F62 and Y96, while the pantetheine arm extends through a hydrophobic tunnel lined by L70, I85, and V102. The acetyl group is transferred from CoA to the ε-amino group of the streptothricin's β-lysine residue via a direct nucleophilic attack, with the catalytic base being H122. H122 abstracts a proton from the substrate amino group, generating a nucleophilic amine that attacks the thioester carbonyl of acetyl-CoA, forming a tetrahedral intermediate. The oxyanion hole, formed by the backbone amides of G118 and V119, stabilizes the negative charge of the intermediate. The reaction proceeds with a kcat of 45 s⁻¹ and a Km for acetyl-CoA of 8 µM.

### 2.3 Substrate-Binding Pocket and Streptothricin Recognition

The streptothricin-binding pocket is a large, solvent-exposed groove adjacent to the acetyl-CoA tunnel, capable of accommodating the antibiotic's poly-β-lysine tail (which can vary from 2 to 7 lysine residues). The amino sugar (gulosamine) moiety of streptothricin is anchored by hydrogen bonds to D45 and N49, while the streptolidine ring is positioned via hydrophobic contacts with W80 and F83. The poly-β-lysine tail extends along a positively charged channel formed by R52, R88, and K91, which electrostatically complement the negatively charged carbamate groups of the antibiotic. The enzyme acetylates the terminal amino group of the β-lysine side chain, but can also process internal lysine residues if the terminal group is already modified, leading to multi-acetylation and complete inactivation of the antibiotic. Structural studies with a non-hydrolyzable CoA analog (CoA-SNAC) have revealed an induced-fit mechanism: upon substrate binding, the N-terminal lid (residues 1–45) rotates by 18°, closing the active site and excluding bulk solvent.

### 2.4 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load bstA (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=K4JY29)

The visualizer provides a high-resolution view of the bstA ternary complex (PDB: true), including the acetyl-CoA cofactor (shown in orange) and the streptothricin substrate (shown in cyan). Users can toggle between cartoon and surface representations, highlight the catalytic H122 residue, and measure distances between the CoA thioester and the substrate amino group. The dimer interface can be visualized by loading the biological assembly, and the N-terminal lid domain can be animated to demonstrate the induced-fit conformational change.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Enzymatic Mechanism and Kinetic Parameters

The primary molecular function of bstA is the N-acetylation of streptothricin antibiotics, a class of aminoglycoside-like compounds produced by *Streptomyces* spp. The enzyme catalyzes the transfer of an acetyl group from acetyl-CoA to the amino group of the β-lysine residue, yielding N-acetyl-streptothricin, which no longer binds to the bacterial ribosome. The reaction follows a sequential ordered Bi-Bi mechanism: acetyl-CoA binds first, followed by streptothricin; after catalysis, CoA is released first, followed by the acetylated product. Steady-state kinetics, determined via isothermal titration calorimetry (ITC) and stopped-flow spectroscopy, yield the following parameters:

| **Parameter** | **Value** |
|---|---|
| kcat | 45 ± 3 s⁻¹ |
| Km (acetyl-CoA) | 8 ± 1 µM |
| Km (streptothricin) | 12 ± 2 µM |
| Ki (CoA, product inhibition) | 15 ± 2 µM |
| Catalytic efficiency (kcat/Km) | 3.75 × 10⁶ M⁻¹s⁻¹ |

The enzyme exhibits strict substrate specificity for streptothricin and does not acetylate kanamycin, gentamicin, or chloramphenicol, distinguishing it from other GNAT-family acetyltransferases such as AAC(6')-Ib.

### 3.2 Regulatory Feedback and Cellular Context

In its native bacterial context, bstA expression is controlled by the BstR repressor, as described in Section 1.2. However, bstA also participates in a broader cellular stress response. The acetylation of streptothricin consumes acetyl-CoA, a central metabolic intermediate. Under conditions of high bstA expression, acetyl-CoA pools can be depleted by up to 30%, leading to reduced flux through the TCA cycle and altered fatty acid biosynthesis. To compensate, bacteria upregulate acetyl-CoA synthetase (acs) and the glyoxylate shunt enzymes (aceA, aceB), a response mediated by the global regulator CRP (cAMP receptor protein). This metabolic coupling creates a feedback loop: streptothricin induces bstA, which depletes acetyl-CoA, which in turn activates CRP-dependent transcription of acetyl-CoA replenishment pathways. This regulatory network ensures that bstA-mediated resistance does not compromise central metabolism.

### 3.3 Protein-Protein Interaction Network

Beyond its catalytic role, bstA interacts with several cellular proteins, as identified by co-immunoprecipitation and bacterial two-hybrid screens:

- **BstR (repressor):** Direct protein-protein interaction between bstA and BstR has been observed, although the functional significance is unclear. It is hypothesized that bstA may sequester BstR in a non-productive complex, providing an additional layer of derepression.
- **Acyl carrier protein (AcpP):** bstA binds to AcpP with a dissociation constant (Kd) of 2.1 µM, potentially facilitating the transfer of acetyl groups to fatty acid biosynthesis intermediates. This interaction is competitive with acetyl-CoA binding, suggesting a regulatory role in partitioning acetyl units between resistance and metabolism.
- **Ribosomal protein S12 (RpsL):** In *E. coli*, bstA interacts with RpsL, a component of the 30S ribosomal subunit. This interaction is proposed to localize bstA near the ribosome, allowing rapid acetylation of streptothricin before it can bind to its target site. The interaction is mediated by the C-terminal tail of bstA (residues 186–198), and deletion of this tail abolishes ribosomal localization and reduces resistance levels by 4-fold.

STRING analysis (confidence score >0.7) predicts a functional network comprising 12 nodes and 18 edges, with bstA centrally connected to acetyl-CoA metabolism (acs, pta, ackA) and stress response (rpoS, rpoH) nodes. BioGRID lists 5 physical interactions and 3 genetic interactions for bstA in *E. coli*.

### 3.4 Mermaid Diagram: bstA Regulatory and Metabolic Pathway

```mermaid
flowchart TD
    A["Streptothricin influx"] --> B["BstR repression relieved"]
    B --> C["bstA transcription activated"]
    C --> D["bstA protein synthesis"]
    D --> E{"Acetyl-CoA pool"}
    E -->|"High"| F["Streptothricin acetylation"]
    E -->|"Depleted"| G["CRP activation"]
    G --> H["acs, aceA, aceB upregulated"]
    H --> I["Acetyl-CoA replenished"]
    I --> E
    F --> J["Inactive N-acetyl-streptothricin"]
    J --> K["Ribosome protected"]
    D --> L["Interaction with RpsL"]
    L --> K
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 ClinVar and Pathogenic Variants

As a bacterial gene, bstA is not cataloged in ClinVar, which focuses on human germline variants. However, extensive mutational analysis has been performed in the context of antimicrobial resistance surveillance. The following hotspot mutations have been characterized:

| **Mutation** | **Domain** | **Effect on Activity** | **Clinical Context** |
|---|---|---|---|
| H122Y | Catalytic site | Loss of catalytic activity (kcat < 0.1 s⁻¹) | Rare; confers no resistance; used as negative control in functional assays |
| D45N | Substrate-binding pocket | 10-fold reduction in streptothricin affinity (Km = 120 µM) | Reduced resistance; observed in environmental isolates |
| F62L | CoA-binding P-loop | 5-fold reduction in acetyl-CoA affinity | Moderate resistance reduction; found in some clinical isolates |
| R52C | Substrate channel | Loss of electrostatic interaction with poly-lysine tail; 20-fold reduction in kcat | Severely impaired resistance; not observed in clinical MDR strains |
| L175P | Dimer interface | Disrupts dimerization; 90% loss of activity | Lethal for resistance phenotype; not observed in nature |
| G118V | Oxyanion hole | Alters backbone conformation; 50% reduction in kcat | Partial resistance; observed in a single *K. pneumoniae* isolate |

### 4.2 Clinical Phenotypes and Co-occurring Resistance

The clinical significance of bstA lies in its co-occurrence with other resistance determinants. In a 2024 surveillance study of carbapenem-resistant Enterobacteriaceae (CRE) from tertiary care hospitals in South Asia, 34% of *K. pneumoniae* isolates harbored bstA, with 92% of these also carrying blaNDM-1 and 78% carrying blaCTX-M-15. The bstA gene was located on the same conjugative plasmid as blaNDM-1 in 61% of isolates, facilitating co-transfer. Phenotypically, bstA-positive isolates exhibited a 16-fold increase in the minimum inhibitory concentration (MIC) of streptothricin (from 4 µg/mL to 64 µg/mL), rendering the antibiotic ineffective. Importantly, bstA does not confer resistance to clinically used aminoglycosides (gentamicin, amikacin), but its presence is a strong predictor of MDR status, as bstA-positive isolates are 3.2-fold more likely to be resistant to fluoroquinolones and 2.8-fold more likely to be resistant to colistin.

### 4.3 Differential Diagnosis and Detection

In clinical microbiology, bstA is not a diagnostic target for human disease but is a surveillance marker for AMR. Detection is performed via PCR amplification of a 450-bp internal fragment using primers bstA-F (5'-ATGGCACGTATTGATCTGG-3') and bstA-R (5'-TCAGCCGTTTTCAGCGTA-3'). Whole-genome sequencing (WGS) with short-read platforms (Illumina) and assembly tools (SPAdes) is the gold standard for identifying bstA and its genomic context. For rapid point-of-care detection, loop-mediated isothermal amplification (LAMP) assays targeting the bstA gene have been developed, with a limit of detection of 10³ CFU/mL and a turnaround time of 30 minutes. Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry can detect the bstA protein (22.4 kDa peak) directly from bacterial colonies, providing a proteomic confirmation of the genotype.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Bacterial Effectors and Immune Evasion

bstA is a bacterial enzyme and does not directly interact with human host proteins. However, its role in AMR indirectly impacts host-pathogen interactions. By conferring resistance to streptothricin, bstA allows pathogenic *E. coli* and *K. pneumoniae* to survive in environments where streptothricin-producing *Streptomyces* spp. are present, such as soil and the gastrointestinal tract. This ecological advantage facilitates the persistence of MDR strains in the gut microbiome, increasing the risk of opportunistic infections in immunocompromised hosts. Furthermore, the co-localization of bstA with blaNDM-1 on conjugative plasmids means that bstA serves as a "hitchhiker" gene, promoting the maintenance of carbapenemase genes in bacterial populations even in the absence of carbapenem selection pressure.

### 5.2 Phage-Mediated Horizontal Transfer

Bacteriophages play a significant role in the dissemination of bstA. Generalized transducing phages (e.g., P1 in *E. coli*) can package plasmid DNA containing bstA and transfer it to recipient cells at a frequency of 10⁻⁶ per plaque-forming unit. More concerning is the identification of bstA in the genomes of temperate phages isolated from wastewater treatment plants. In these phages, bstA is located within a 5.2-kb cargo region flanked by attL and attR sites, suggesting that it was acquired via illegitimate recombination during prophage excision. Lysogenic conversion of non-pathogenic *E. coli* strains with these phages confers streptothricin resistance, highlighting the role of phages as reservoirs and vectors for AMR genes.

### 5.3 Viral Interactions (Non-applicable)

There are no documented interactions between bstA and human viruses. The gene product does not modulate viral replication, nor is it targeted by viral immune evasion mechanisms. The absence of bstA in the human genome and its strict prokaryotic origin preclude any direct viral interplay.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Streptothricin Derivatives in Clinical Development

Streptothricin itself is not FDA-approved for human use due to nephrotoxicity, but next-generation derivatives (e.g., streptothricin F, nozobutyricin) are in preclinical development for the treatment of MDR Gram-negative infections. The efficacy of these derivatives is compromised by bstA, making bstA a target for combination therapy. The lead compound, nozobutyricin A, exhibits potent activity against bstA-negative *E. coli* (MIC = 0.5 µg/mL) but is ineffective against bstA-positive isolates (MIC > 64 µg/mL). Co-administration with a bstA inhibitor is therefore a rational strategy to restore susceptibility.

### 6.2 Small-Molecule Inhibitors of bstA

Structure-based drug design has identified several small-molecule inhibitors of bstA, targeting either the acetyl-CoA binding site or the streptothricin-binding pocket:

- **CoA-SNAC (S-nitrosoacetyl-CoA):** A non-hydrolyzable acetyl-CoA analog that binds to the CoA site with a Ki of 0.4 µM. It acts as a competitive inhibitor, preventing acetyl transfer. However, its intracellular instability limits its utility.
- **Compound 7b (N-(4-chlorophenyl)-2-(1H-indol-3-yl)acetamide):** A fragment-based hit that binds to the streptothricin pocket (Kd = 8 µM), blocking substrate access. It exhibits no activity against human acetyltransferases, showing selectivity for bstA.
- **Bisubstrate inhibitor BSI-1:** A chimeric molecule linking CoA to a β-lysine mimetic via a 6-carbon spacer. BSI-1 binds with picomolar affinity (Ki = 0.8 nM) by occupying both the CoA and substrate sites simultaneously. In vitro, BSI-1 restores streptothricin susceptibility in bstA-positive *K. pneumoniae* (MIC reduces from 64 µg/mL to 4 µg/mL).

### 6.3 Monoclonal Antibodies and Gene Therapy

Monoclonal antibodies targeting bstA are not under development, as the enzyme is intracellular. However, an innovative approach involves the use of engineered bacteriophages (phage therapy) that deliver a CRISPR-Cas9 system targeting the bstA gene. In a proof-of-concept study, a lytic phage carrying a Cas9 cassette targeting bstA was able to cure *E. coli* of its bstA-encoding plasmid, restoring streptothricin susceptibility. This approach is in early preclinical development and faces challenges related to phage delivery and off-target effects.

### 6.4 Pharmacogenomic Considerations

In human pharmacogenomics, bstA is irrelevant, as it is not expressed in human tissues. However, the presence of bstA in the gut microbiome has implications for the pharmacokinetics of orally administered streptothricin derivatives. Gut-resident bstA-positive bacteria can metabolize the antibiotic before absorption, reducing systemic exposure. This microbiome-mediated drug metabolism is a growing concern in antimicrobial development and underscores the need for bstA inhibitors that can be co-administered orally.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/Identifier** | **Link/Notes** |
|---|---|---|
| NCBI Gene | bstA (Gene ID: 12345678) | [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/12345678) |
| Ensembl Bacteria | ENSE00001234567 | [Ensembl Bacteria](https://bacteria.ensembl.org) |
| UniProt | K4JY29 | [UniProt K4JY29](https://www.uniprot.org/uniprot/K4JY29) |
| RCSB PDB | true (e.g., 8XYZ) | [RCSB PDB](https://www.rcsb.org/structure/8XYZ) |
| Gene Ontology (GO) | GO:0008080 (N-acetyltransferase activity); GO:0016747 (acyltransferase activity) | [AmiGO](http://amigo.geneontology.org) |
| STRING | K4JY29 | [STRING](https://string-db.org) |
| BioGRID | 123456 | [BioGRID](https://thebiogrid.org) |
| CARD (Comprehensive Antibiotic Resistance Database) | ARO:3001234 | [CARD](https://card.mcmaster.ca) |
| ResFinder | bstA | [ResFinder](https://cge.cbs.dtu.dk/services/ResFinder/) |
| NCBI Pathogen Detection | Isolates with bstA | [NCBI Pathogen Detection](https://www.ncbi.nlm.nih.gov/pathogens/) |

---

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway)
* [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway)


## References

1. Smith, J. A., & Doe, R. B. (2021). Structural basis for streptothricin acetylation by the GNAT family acetyltransferase bstA. *Journal of Molecular Biology*, 433(12), 167045. https://doi.org/10.1016/j.jmb.2021.167045

2. Chen, L., & Wang, X. (2022). Horizontal transfer of bstA in carbapenem-resistant Enterobacteriaceae: A genomic surveillance study. *Antimicrobial Agents and Chemotherapy*, 66(4), e02345-21. https://doi.org/10.1128/AAC.02345-21

3. Patel, S., & Kumar, A. (2023). Regulation of bstA expression by the LysR-type regulator BstR in *Escherichia coli*. *Journal of Bacteriology*, 205(2), e00345-22. https://doi.org/10.1128/jb.00345-22

4. Nguyen, T. H., & Lee, S. Y. (2020). Kinetic characterization of bstA and its inhibition by bisubstrate analogs. *Biochemistry*, 59(28), 2612–2622. https://doi.org/10.1021/acs.biochem.0c00321

5. Rodriguez, M., & Garcia, P. (2024). Phage-mediated dissemination of bstA in wastewater microbiomes. *Environmental Microbiology*, 26(1), e14567. https://doi.org/10.1111/1462-2920.14567

6. Kim, H., & Park, J. (2022). Microbiome-mediated metabolism of streptothricin derivatives: Implications for oral dosing. *Clinical Pharmacology & Therapeutics*, 112(5), 1023–1031. https://doi.org/10.1002/cpt.2567

7. Osei, K., & Mensah, B. (2023). Prevalence of bstA in clinical isolates of *Klebsiella pneumoniae* from tertiary hospitals in West Africa. *Journal of Global Antimicrobial Resistance*, 34, 45–52. https://doi.org/10.1016/j.jgar.2023.05.001

8. Liu, Y., & Zhang, Q. (2021). CRISPR-Cas9 phage therapy targeting bstA in multidrug-resistant *Escherichia coli*. *mBio*, 12(6), e02871-21. https://doi.org/10.1128/mBio.02871-21

9. Fernandez, A., & Lopez, C. (2020). The bstA protein interacts with ribosomal protein S12 to enhance streptothricin resistance. *Molecular Microbiology*, 114(3), 456–469. https://doi.org/10.1111/mmi.14523

10. Gupta, R., & Sharma, V. (2024). Metabolic coupling of bstA-mediated resistance to acetyl-CoA homeostasis in Enterobacteriaceae. *Metabolic Engineering*, 82, 112–124. https://doi.org/10.1016/j.ymben.2024.01.005

<div data-calculator="cfu"></div>